PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Habegger, K.M.* ; Heppner, K.M.* ; Amburgy, S.E.* ; Ottaway, N.* ; Holland, J.* ; Raver, C.* ; Bartley, E.* ; Müller, T.D. ; Pfluger, P.T. ; Berger, J.* ; Toure, M.* ; Benoit, S.C.* ; DiMarchi, R.D.* ; Perez-Tilve, D.* ; D'Alessio, D.A.* ; Seeley, R.J.* ; Tschöp, M.H.

GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats.

Diabetes 63, 505-513 (2014)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Several bariatric operations are currently used to treat obesity and obesity-related comorbidities. These vary in efficacy, but most are more effective than current pharmaceutical treatments. Roux-en-Y Gastric Bypass (RYGB) produces substantial body weight (BW) loss, enhanced glucose tolerance, and is associated with increased secretion of the gut hormone GLP-1. Given the success of GLP-1-based agents in lowering blood glucose and BW, we hypothesized that an individual sensitivity to GLP-1 receptor agonism could predict metabolic benefits of surgeries associated with increased GLP-1 secretion. One hundred ninety-seven high-fat-diet-induced obese male Long-Evans rats were monitored for BW loss during Exendin-4 (Ex4) administration. Stable populations of responders and non-responders were identified based on Ex4-induced BW loss and GLP-1-induced improvements in glucose tolerance. Sub-populations of Ex4 extreme responders and non-responders received RYGB. Following RYGB, responders and non-responders showed similar BW loss compared to sham, but non-responders retained impaired glucose tolerance. These data indicate that the GLP-1 response tests may predict some but not all of the improvements observed after RYGB. These findings present an opportunity to optimize the use of bariatric surgery based on an improved understanding of GLP-1 biology and suggest an opportunity for a more personalized therapeutic approach to the metabolic syndrome.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
7.895
2.164
32
33
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Glucagon-like Peptide-1; Vertical Sleeve Gastrectomy; Weight-loss; Exenatide Treatment; Surgery; Obesity; Metaanalysis; Overweight
Sprache englisch
Veröffentlichungsjahr 2014
Prepublished im Jahr 2013
HGF-Berichtsjahr 2013
ISSN (print) / ISBN 0012-1797
e-ISSN 1939-327X
Zeitschrift Diabetes
Quellenangaben Band: 63, Heft: 2, Seiten: 505-513 Artikelnummer: , Supplement: ,
Verlag American Diabetes Association
Verlagsort Alexandria, VA.
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502200-001
G-501900-221
PubMed ID 24186863
DOI 10.2337/db13-0511
WOS ID WOS:000331110000019
Erfassungsdatum 2013-11-08
[➜Korrektur melden]